AX-2026-041313

ARA-290 · 4 mg declared · Wuhan Wansheng Biotechnology Co., Ltd. · lot WWB-2511-S3009

PASSVERIFIED

Report ID: AX-2026-041313
Compound: ARA-290
Compound class: Tissue-repair and immunomodulatory peptides
Supplier: WWB — Wuhan Wansheng Biotechnology Co., Ltd.
Batch / lot: WWB-2511-S3009
Declared label claim: 4mg
Laboratory: Nordanalyt Laboratories
Assay date: 10 Mar 2026
Submitted: 01 Apr 2026
Quarter: 2026-Q1
Submitter: m/z_marta
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	99.93	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.07	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — acetyl adduct (+42 Da)	0.04	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	1189.6096	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	1189.6148	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+4.4	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	4.81	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.21	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.49	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	1.54	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	6.28	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	10.15	min	10.06 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.99	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	78,361	—	≥ 20,000	PASS
Resolution to nearest impurity	vs deamidated (+1 Da)	1.73	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 78,361, and skew follows the reported asymmetry factor of 0.99. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.04 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	ARA-290 — main peak	10.15	4,856,908	99.93	—
2	acetyl adduct (+42 Da)	10.62	1,944	0.04	+42.011
3	deamidated (+1 Da)	9.89	1,458	0.03	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1189.6096 Da, computed from C50H83N15O18. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1189.6148 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
3+	397.5438	397.5455	0.0017	7.9
2+	595.8121	595.8147	0.0026	54.1
1+	1190.6169	1190.6221	0.0052	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.93	divergence -0.03 pp vs batch median
Total impurities (% area)	0.10	0.07
Largest single impurity (% area)	0.07	0.04
Water (%)	2.5	4.81
Counter-ion (%)	6.5	4.21
Peptide content (%w/w)	90.4	not determined
Endotoxin (EU/mg)	0.96	1.54
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 8 d) → assay. Submitter did not handle the vial.
Assay date: 10 Mar 2026
Submitted to the index: 01 Apr 2026
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot WWB-2511-S3009 n=10

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041314	WWB-2511-S3009	PeptideMeter	2026-Q1	99.45	4.87	—	Laboratory-retained	1	MARGINAL
AX-2026-041315	WWB-2511-S3009	PeptideMeter	2026-Q1	99.93	4.83	98.4	Supplier-supplied	0	PASS
AX-2026-041316	WWB-2511-S3009	Janoshik	2026-Q1	99.79	5.17	—	Supplier-supplied	0	PASS
AX-2026-041317	WWB-2511-S3009	Janoshik	2026-Q1	99.93	4.60	—	Supplier-supplied	0	PASS
AX-2026-041318	WWB-2511-S3009	Medutest	2026-Q1	99.93	4.44	107.4	Supplier-supplied	0	PASS
AX-2026-041319	WWB-2511-S3009	PeptideMeter	2026-Q1	99.88	5.10	89.2	Supplier-supplied	2	MARGINAL
AX-2026-041320	WWB-2511-S3009	Janoshik	2026-Q1	99.42	5.13	—	Laboratory-retained	1	MARGINAL
AX-2026-041321	WWB-2511-S3009	Janoshik	2026-Q1	99.93	4.64	93.0	Supplier-supplied	0	PASS
AX-2026-041322	WWB-2511-S3009	Janoshik	2026-Q1	99.93	5.26	—	Supplier-supplied	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent ARA-290 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041852	JEEP	JEEP-2601-K3139	Janoshik	2026-Q2	99.03	4.60	—	Buyer-sourced	1	MARGINAL
AX-2026-043211	SGN	SGN-2605-X9661	PeptideMeter	2026-Q2	97.96	7.11	101.7	Supplier-supplied	1	FAIL
AX-2026-041857	JEEP	JEEP-2601-K3139	Kestrel	2026-Q2	99.09	4.21	—	Supplier-supplied	1	MARGINAL
AX-2026-043212	SGN	SGN-2605-X9661	PeptideMeter	2026-Q2	98.58	7.00	—	Supplier-supplied	1	MARGINAL
AX-2026-041853	JEEP	JEEP-2601-K3139	PeptideMeter	2026-Q2	98.50	4.51	94.7	Laboratory-retained	1	MARGINAL
AX-2026-041856	JEEP	JEEP-2601-K3139	Janoshik	2026-Q2	99.63	4.29	92.0	Supplier-supplied	1	MARGINAL
AX-2026-041851	JEEP	JEEP-2601-K3139	Janoshik	2026-Q2	99.00	4.51	—	Supplier-supplied	1	MARGINAL
AX-2026-041858	JEEP	JEEP-2601-K3139	VendorInvestigate	2026-Q2	98.82	4.14	—	Buyer-sourced	1	MARGINAL

Other recent WWB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041275	Liraglutide	WWB-2607-X2189	Nordanalyt	2026-Q3	99.61	5.03	97.3	Supplier-supplied	0	PASS
AX-2026-041387	BPC-157	WWB-2606-H3906	Janoshik	2026-Q3	98.95	4.64	—	Laboratory-retained	1	MARGINAL
AX-2026-041334	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	98.83	5.04	—	Supplier-supplied	1	MARGINAL
AX-2026-041337	Semaglutide	WWB-2606-N3192	Nordanalyt	2026-Q3	98.96	4.81	—	Supplier-supplied	1	MARGINAL
AX-2026-041385	BPC-157	WWB-2606-H3906	Medutest	2026-Q3	99.31	4.31	—	Supplier-supplied	1	MARGINAL
AX-2026-041390	BPC-157	WWB-2606-H3906	Medutest	2026-Q3	99.47	4.84	99.3	Supplier-supplied	1	MARGINAL
AX-2026-041386	BPC-157	WWB-2606-H3906	VendorInvestigate	2026-Q3	99.32	4.88	99.2	Buyer-sourced	1	MARGINAL
AX-2026-041335	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	99.55	4.55	100.5	Supplier-supplied	1	MARGINAL